Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at UPMC (University of Pittsburgh)

Sites in Pittsburgh, PA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 2:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1600
Shown on this page
12
Current sort
Recently updated
Campus scope
UPMC (University of Pittsburgh), Pittsburgh, PA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within UPMC (University of Pittsburgh), Pittsburgh, PA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 877–888 of 1,600 matching trials with a site at UPMC (University of Pittsburgh), Pittsburgh, PA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 4 Interventional

Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy

NCT05180773
Status at this site: Recruiting
View directory record Official record
Conditions
Peripartum Cardiomyopathy, Postpartum
Interventions
Bromocriptine, Placebo, Guideline Directed Medical Therapy for Heart Failure (GDMT), Rivaroxaban, Second Placebo
Drug
Lead sponsor
Dennis M. McNamara, MD, MS
Other
Eligibility
18 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
64
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 5, 2026, 2:33 PM EST
Recruiting Not applicable Interventional

Subcortical Arousal in Perceptual Awareness

NCT06934356
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Epilepsy
Interventions
EEG, Eye Tracking, Behavioral task, fMRI
Device · Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
13 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
8
States / cities
New Haven, Connecticut • Kansas City, Kansas • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 5, 2026, 2:33 PM EST
Recruiting Phase 1 Interventional

Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients

NCT07583251
Status at this site: Recruiting
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI)
Interventions
Gamma- Glutamylcysteine, Gamma- Glutamylcusteine
Drug
Lead sponsor
Pravat Mandal
Other
Eligibility
55 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Nov 5, 2026, 2:33 PM EST
Active, not recruiting Phase 1 Interventional

Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol

NCT03997370
Site status not listed — check the official record
View directory record Official record
Conditions
Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Carboplatin, Iohexol
Procedure · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
179
States / cities
Tucson, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 134 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Nov 5, 2026, 2:33 PM EST
Recruiting Phase 3 Interventional

Evaluation of Analgesia for Cardiac Elective Surgery in Children

NCT06626035
Status at this site: Recruiting
View directory record Official record
Conditions
Pediatric Cardiac Surgery
Interventions
Methadone based ERAS, Non-methadone based group
Drug
Lead sponsor
Senthil Sadhasivam
Other
Eligibility
3 Years to 18 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Oakland, California • Cincinnati, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Nov 5, 2026, 2:33 PM EST
Recruiting Not applicable Interventional

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

NCT04251052
Status at this site: Recruiting
View directory record Official record
Conditions
Ovarian Carcinoma
Interventions
Bilateral Salpingectomy, Bilateral Salpingectomy with Oophorectomy, Biospecimen Collection, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Transvaginal Ultrasound, Ultrasound Imaging
Procedure · Other
Lead sponsor
NRG Oncology
Other
Eligibility
35 Years to 50 Years · Female only
Enrollment
1,956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2047
U.S. locations
564
States / cities
Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 372 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Nov 5, 2026, 2:33 PM EST
Recruiting No phase listed Observational

Prospective Multicenter Research on Donor and Recipient Management Strategies to Improve Lung Transplant Outcomes

NCT06399302
Status at this site: Recruiting
View directory record Official record
Conditions
Lung Transplant; Complications, Lung Transplant; Infection or Inflammation, Lung Transplant Rejection, Lung Transplant Failure
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
18
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Nov 5, 2026, 2:33 PM EST
Recruiting Phase 2 Interventional

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

NCT05999994
Status at this site: Recruiting
View directory record Official record
Conditions
Neoplasms, Child, Adolescent
Interventions
Ramucirumab, Cyclophosphamide, Vinorelbine, Gemcitabine, Docetaxel, Abemaciclib, Irinotecan, Temozolomide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
1 Year to 39 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Nov 5, 2026, 2:33 PM EST
Recruiting Phase 4 Interventional

Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma

NCT04743791
Status at this site: Recruiting
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo
Drug · Other
Lead sponsor
Sally E. Wenzel MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Nov 5, 2026, 2:33 PM EST
Active, not recruiting Phase 3 Interventional

Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study

NCT04089358
Site status not listed — check the official record
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Educational Intervention, FitBit, Goal Setting, Health Promotion and Education, Media Intervention, Telephone-Based Intervention
Other · Device · Behavioral
Lead sponsor
Children's Oncology Group
Network
Eligibility
15 Years to 20 Years
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
114
States / cities
Mobile, Alabama • Mesa, Arizona • Downey, California + 92 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Nov 5, 2026, 2:33 PM EST
Active, not recruiting Phase 1 Interventional

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

NCT05483868
Site status not listed — check the official record
View directory record Official record
Conditions
Non-muscle-invasive Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Carcinoma, Non-Muscle Invasive Bladder Neoplasms, Non-Muscle Invasive Bladder Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions
AU-011, AU-011 in Combination with Medical Laser Adminstration, AU-011 in Combination with Medical Laser Administration
Drug · Combination Product
Lead sponsor
Aura Biosciences
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
13
States / cities
Little Rock, Arkansas • Los Angeles, California • Santa Monica, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Nov 5, 2026, 2:33 PM EST
Active, not recruiting Phase 2 Interventional

STOP-HER2: Stopping Trastuzumab in HER2+ MBC

NCT05721248
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer
Interventions
Cessation of anti-HER2 treatment
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
13
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Nov 5, 2026, 2:33 PM EST

About this UPMC (University of Pittsburgh) institution page

What this page lists
ClinicalTrials.gov records that list UPMC (University of Pittsburgh) in Pittsburgh, PA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.